K Number
K143443
Date Cleared
2015-03-25

(113 days)

Product Code
Regulation Number
888.3560
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The VEGA Knee System is indicated for use in reconstruction of the diseased by ostearthritis, theumatoid arthritis, post-traumatic arthritis, the need to revise failed arthroplasties where pain, deformity or dysfunction persist, and for patients suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for aon-functioning posterior cruciate ligament and severe anteroposterior instability of the knee joint.

The VEGA Knee is designed for use with bone cement.

The Columbus Total Knee System is indicated for use in reconstruction of the diseased by osteoarthritis, theumatord arthritis, post-traumatic arthritis, the need to revise failed arthroplasties where pain, deformity or dysfunction persist, and for patients suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for and on non-functioning posterior cruciate ligament and severe anteroposterior instability of the knee joint.

The Columbus Knee is designed for use with bone cement.

Device Description

All Poly Tibia posterior stabilizing and cruciate retaining implants are a line extension to the VEGA Knee System® and Columbus Total Knee System, respectively. The posterior stabilizing version is being introduced to the VEGA Knee System® and the cruciate retaining, deep dish version is being introduced to the Columbus Total Knee System. The subject implants are available with an optional centralizer.

VEGA Knee System® is a semi-constrained cemented prosthesis with a posterior stabilized (PS) design. Columbus Total Knee System includes both cruciate retaining and posterior stabilizing variants of the femoral, tibial and meniscal components.

For both knee systems, the femoral component, tibial plateau and extension stems are manufactured from Cobalt Chromium Molybdenum alloy (CoCrMo), available with an optional Zirconium nitride (ZrN) coating. The tibial gliding surface (insert), patella and All Poly Tibia are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE). The optional centralizer, designed to be used with the All Poly Tibia is made of polymethyl methacrylate (PMMA). The patella and All Poly Tibia incorporate X-ray markers. The materials of the X-ray markers in the patella are wrought stainless steel and the All Poly Tibia X-ray markers consist of a titanium peg and a tantalum ball. The tibial plug is made of PEEK.

VEGA and Columbus Knee Systems are made up of numerous components available in various sizes. The VEGA Knee System® is compatible with Aesculap Columbus cruciate retaining/posterior stabilizing tibial plateaus (CR/PS and CRA/PSA) and augments.

VEGA and Columbus components are sterile and intended for single use only.

AI/ML Overview

The provided document is a 510(k) premarket notification for the VEGA Knee System® and Columbus Total Knee System, specifically regarding the introduction of All Poly Tibia posterior stabilizing and cruciate retaining implants with an optional centralizer. It describes the device, its intended use, and its substantial equivalence to previously marketed devices. However, the document does not contain acceptance criteria for device performance or a study proving that the device meets such criteria.

Instead, it focuses on demonstrating substantial equivalence to predicate devices by addressing technological characteristics and manufacturing processes. The "Performance Data" section briefly mentions:

  • A risk analysis.
  • Biomechanical testing.
  • A comparison evaluation of wear.
  • Biocompatibility of X-ray markers.
  • Validation and verification of new instruments.

The conclusion of this section is that these analyses "raised no new issues of safety and efficacy for the design modifications described herein." This indicates that the intent was to show that the new components did not negatively impact the established safety and efficacy of the existing systems, rather than to present new acceptance criteria or a study demonstrating achievement of those criteria.

Therefore, I cannot provide the requested information from the given text as it is not present. The document focuses on regulatory approval through substantial equivalence, not on quantifiable performance acceptance criteria and a study demonstrating their achievement.

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three faces in profile, stacked on top of each other. The faces are silhouetted and appear to be looking to the right. The logo is surrounded by a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" written around it.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

March 25, 2015

Aesculap Implant Systems, LLC Ms. Lisa Boyle Regulatory Affairs Manager 3773 Corporate Parkway Center Valley, Pennsylvania 18034

Re: K143443

Trade/Device Name: VEGA Knee System® and Columbus Total Knee System Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis Class: Class II Product Code: JWH

Dated: February 20, 2015 Received: February 23, 2015

Dear Ms. Boyle:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Lori A. Wiggins -S

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

See PRA Statement on last page.

K143443 Paqe 1/1

510(k) Number (if known)

K143443

Device Name

VEGA Knee System and Columbus Total Knee System

Indications for Use (Describe)

The VEGA Knee System is indicated for use in reconstruction of the diseased by ostearthritis, theumatoid arthritis, post-traumatic arthritis, the need to revise failed arthroplasties where pain, deformity or dysfunction persist, and for patients suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for aon-functioning posterior cruciate ligament and severe anteroposterior instability of the knee joint.

The VEGA Knee is designed for use with bone cement.

The Columbus Total Knee System is indicated for use in reconstruction of the diseased by osteoarthritis, theumatord arthritis, post-traumatic arthritis, the need to revise failed arthroplasties where pain, deformity or dysfunction persist, and for patients suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for and on non-functioning posterior cruciate ligament and severe anteroposterior instability of the knee joint.

The Columbus Knee is designed for use with bone cement.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

{3}------------------------------------------------

K143443

Page 1 of 2

510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

VEGA Knee System and Columbus Total Knee System

February 20, 2015

COMPANY:Aesculap® Implant Systems, LLC
3773 Corporate Parkway
Center Valley, PA 18034
ESTABLISHMENT3773 Corporate ParkwayCenter Valley, PA 18034
REGISTRATION NUMBER:3005673311
CONTACT:Lisa M. Boyle
610-984-9274 (phone)
610-791-6882 (fax)
lisa.boyle@aesculap.com
DEVICE TRADE NAMES:VEGA Knee System®
Columbus Total Knee System
COMMON NAME:Total Knee System
DEVICE CLASS:CLASS II
PRODUCT CODE:JWH
REGULATION NUMBER:888.3560
CLASSIFICATION NAME:Knee Joint Patellofemorotibial Polymer/Metal/Polymer Semi constrained Cemented Prosthesis

SUBSTANTIAL EQUIVALENCE

Aesculap Implant Systems, LLC believes that the introduction of All Poly Tibia posterior stabilizing and cruciate retaining implants with an optional centralizer are substantially equivalent to the currently marketed Aesculap VEGA Knee System® (K101281, K121879, K140452, and K143106), Columbus Total Knee System (K022672; K023788; K053390; K071220; K071449 and K120955) and Triathlon® All-Polyethylene Tibial Implants (K123166).

DEVICE DESCRIPTION

All Poly Tibia posterior stabilizing and cruciate retaining implants are a line extension to the VEGA Knee System® and Columbus Total Knee System, respectively. The posterior stabilizing version is being introduced to the VEGA Knee System® and the cruciate retaining, deep dish version is being introduced to the Columbus Total Knee System. The subject implants are available with an optional centralizer.

VEGA Knee System® is a semi-constrained cemented prosthesis with a posterior stabilized (PS) design. Columbus Total Knee System includes both cruciate retaining and posterior stabilizing variants of the femoral, tibial and meniscal components.

{4}------------------------------------------------

Vega Knee System® Columbus Total Knee System

K143443 Page 2 of 2

For both knee systems, the femoral component, tibial plateau and extension stems are manufactured from Cobalt Chromium Molybdenum alloy (CoCrMo), available with an optional Zirconium nitride (ZrN) coating. The tibial gliding surface (insert), patella and All Poly Tibia are manufactured from Ultra High Molecular Weight Polyethylene (UHMWPE). The optional centralizer, designed to be used with the All Poly Tibia is made of polymethyl methacrylate (PMMA). The patella and All Poly Tibia incorporate X-ray markers. The materials of the X-ray markers in the patella are wrought stainless steel and the All Poly Tibia X-ray markers consist of a titanium peg and a tantalum ball. The tibial plug is made of PEEK.

VEGA and Columbus Knee Systems are made up of numerous components available in various sizes. The VEGA Knee System® is compatible with Aesculap Columbus cruciate retaining/posterior stabilizing tibial plateaus (CR/PS and CRA/PSA) and augments.

VEGA and Columbus components are sterile and intended for single use only.

INDICATIONS FOR USE

The VEGA Knee System® and the Columbus Total Knee System are indicated for use in reconstruction of the diseased knee joint caused by osteoarthritis, rheumatoid arthritis, posttraumatic arthritis, the need to revise failed arthroplasties or osteotomies where pain, deformity or dysfunction persist, and for patients suffering from correctable valgus or varus deformity and moderate flexion contracture.

Posterior Stabilized (PS) components are also for absent or non-functioning posterior cruciate ligament and severe anteroposterior instability of the knee ioint.

The VEGA Knee System® and Columbus Total Knee System are designed for use with bone cement.

TECHNOLOGICAL CHARACTERISTICS

The addition of All Poly Tibia posterior stabilizing and cruciate retaining implants with an optional centralizer does not change the fundamental scientific technology of VEGA Knee System® or of Columbus Total Knee System.

Similar to the Triathlon® All-Polyethylene Posterior Stabilizing (PS) and Condylar Stabilizing (CS) tibial implants (K123166), the introduction of All Poly Tibia is a monoblock meniscal/tibial UHMWPE component whose design is based on the respective system's UHMWPE tibial insert and CoCrMo tibial components.

VEGA All Poly Tibia (PS) components are compatible with the articulating sizes of the VEGA femur and patella. Similarly, Columbus All Poly Tibia (CR deep dish) is compatible with the articulating sizes of the Columbus femur and patella. The optional centralizer was previously cleared in Aesculap's Excia Hip system (K042344). It is designed to ensure a consistent cement mantle around the keel.

PERFORMANCE DATA

As a result of the risk analysis, biomechanical testing and a comparison evaluation of wear was performed. The results of the wear evaluation, mechanical failure (break) and surface roughness analysis raised no new issues of safety and efficacy for the design modifications described herein. In addition to the data above, biocompatibility of the X-ray markers was provided as well as information on the validation and verification of the new instruments.

§ 888.3560 Knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis.

(a)
Identification. A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).(b)
Classification. Class II.